ClinicalTrials.gg
CompletedNCT03003000Updated Jun 7, 2019Results posted

Ibuprofen/Caffeine Lower Back or Neck Pain Study

A Phase 3 interventional study of ibuprofen and caffeine in Back Pain and Neck Pain, sponsored by Boehringer Ingelheim. Completed at 18 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-07.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
635
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 28 studies in Back Pain with a site in Germany — 5 open to participants now, 5 under way, 2 of them phase 3. Back Pain · Germany.

Enrollment
2nd of 25
635 · median 165
Started
2016
the only one that year
Phase 3
9 of 28
2 open now
Registered
21st of 28
by date
Lead sponsor
1 of 28
Boehringer Ingelheim

Among the 28 studies in Back Pain with a site in Germany, this one is the 2nd largest by enrollment of the 25 interventional ones that give a count, is the only one that started in 2016, is one of 9 in phase 3, and was the 21st registered.

Back Pain

728 studies on the registry are indexed under Back Pain; 109 are open to participants now.

Browse Back Pain studies →

Open to participants now

5 of the 28 studies in Back Pain with a site in Germany are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 68 Back Pain studies recruiting now, 29 (43%) set no upper age limit and 32 (47%) stop at 75 or younger; 3 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Back Pain with a site in Germany, or all of them as a file.
02

Study summary

To assess the efficacy and safety of a 400 mg ibuprofen/100 mg caffeine tablet in comparison to a 400 mg ibuprofen tablet for the treatment of acute lower back or neck pain. To assess the safety and tolerability of a 400 mg ibuprofen/100 mg caffeine tablet in comparison to a 400 mg ibuprofen tablet and a placebo tablet.

03

Conditions studied

  • Back Pain
  • Neck Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed and dated written at Visit 1 in accordance with Good Clinical Practice (GCP) and local legislation.
  • Male or female patients who are >=18 years with current diagnosis of acute back pain or of neck pain for at least 24 hours, but less than 21 days.
  • Acute back pain or acute neck pain resulting in Pain on Movement (POM) >=5 on the 0-10 Numerical Rating Scale (NRS) for at least one POM procedure out of 5 standardised procedures.
  • Sensitivity to algometric pressure on the painful trigger point \<= 25 N/cm².
  • Women of must be ready and able to use highly effective methods of .
  • Reliable, cooperative, and of adequate intelligence to record the requested information on the analgesic questionnaires.
  • Examined by the attending physician and medically cleared to participate in the study
  • In good general health, with a (BMI) \< 30, and have no to any of the study medication

Exclusion criteria

Exclusion criteria:

  • History of 3 or more episodes of back or neck pain in the last 6 months excluding the current episode.
  • Patients with pain at rest >= 9
  • Patient with chronic back or neck pain as defined as pain for 3 weeks or longer.
  • Back or neck pain that is attributable to any identifiable cause (eg. disc prolapse, spondylolisthesis, osteomalacia, inflammatory arthritis, metabolic, neurological diseases or tumour)
  • Any strains of the back or neck muscles documented by clinical evaluation and anamnesis that occurred 21 days to 3 months prior to the screening visit.
  • Surgery due to back or neck pain or rehabilitation due to back or neck pain in the last 12 months.
  • Prior use within the last 3 days before Visit 1 or concomitant use of any anti- inflammatory drugs, heparinoids, muscle relaxants or analgesics (including but not limited to short-acting , non-steroidal anti-inflammatory drugs [NSAIDs], herbal preparations) for the same indication or other indications.
  • Spinal injections should have been discontinued in due time (investigator's judgment) before patient enrollment to allow complete wash-out of the active ingredient based on investigator's judgment.
  • Known severe hepatocellular insufficiency, severe renal insufficiency or Gilbert's syndrome (Morbus Meulengracht)
  • Patients taking Central Nervous System (CNS) or other psychotropic drugs, or any nutritional supplement known to have psychotropic effects such as St. John's Wort, Chapparal, Comfrey, Germander, Gin Bu Huan, Kava, Pennyroyal Skullcap, or Valerian within two months of taking the first dose of study medication. Patients who have been on stable doses of these medications for at least two months will be allowed into the study, as long as they maintain this dose throughout the study, and their condition is judged stable by the Principal Investigator
  • Any other medical condition that would interfere with efficacy and safety assessments based on investigator's judgment or any on-going clinical condition that would jeopardize patient's or site personnel's safety or study compliance based on investigator judgment
  • Further exclusion criteria apply
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
635 participants (actual)

Study arms

  • Experimental
    ibuprofen + caffeine

    Fixed Dose Combination

    Drug: ibuprofen · Drug: caffeine

  • Active comparator
    ibuprofen

    Drug: ibuprofen

  • Placebo comparator
    placebo

    Drug: placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake)

    The change in pain on movement (POM) with regard to the worst procedure (WP), i.e. the procedure with the highest pain score at baseline (POMwp), between baseline (morning of Day 1, pre-dosing) and Day 2 (morning, 2 hour (h) after drug intake). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. The procedure resulting in highest POM at baseline (worst procedure, POMWP) was repeated for an individual patient. If 2 or more procedures gave the same highest POM, the patient was asked which of the procedures giving the highest POM scores he/she considered the most unpleasant. Change in POMwp was calculated as baseline POMwp - POMwp at Day 2 - indicating a reduction in POMwp, where the result is positive.

    Time frame: Baseline and Day 2

Secondary outcomes

  1. The Area Under the Curve (AUC) for Pain on Movement (POM) With Regard to the Worst Procedure (POMwp) Between Baseline and Day 4 (Morning) (POMwpAUC72hour (h))

    This is a key secondary endpoint. The area under the curve (AUC) for pain on movement (POM) with regard to the worst procedure (POMwp) between baseline and Day 4 (morning), (POMwpAUC72h ). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp

    Time frame: Baseline, Day 1, Day 2 and Day 4 (morning)

  2. The Area Under the Curve (AUC) for the Procedure With the Highest Pain Score at Baseline (POMWP) Between Baseline and Day 6 (Morning) (POM(WP)AUC(120h))

    This is a key secondary endpoint. The area under the curve for pain on movement with regard to the worst procedure between baseline and Day 6 (morning) (POM(WP)AUC(120h). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp.

    Time frame: Baseline, Day 1, Day 2, Day 4 and Day 6 (morning)

  3. Change in Pressure Algometry Between Baseline and Day 2 (Morning, 2 Hour After Drug Intake)

    Change in pressure algometry between baseline and Day 2 (morning, 2 h after drug intake). Pressure algometry was determined by the investigator as the pressure value (N/cm2) at a defined trigger point which is located in the area of POMWP. The measurement was performed by using a Somedic Algometer (Somedic AB, Sweden) or an equivalent calibrated and certified device. The pain reaction was determined by placing the algometer on the trigger point, i.e. an area of 1 cm² for which the patient indicated most painful tenderness. The pressure was constantly increased until the patient asked not to increase the pressure anymore. Upon this pain reaction, the corresponding pressure value was documented in the Electronic case report form (eCRF). The trigger point was to be marked with a ball pen to be able to repeat the subsequent assessment at the same position. Change in pressure was calculated as baseline pressure - pressure at Day 2, with a negative result indicating an improvement.

    Time frame: Baseline and Day 2 (morning, 2 h after drug intake)

  4. Global Assessment of Efficacy by the Patient at the End of Treatment (Morning of Day 6)

    Global assessment of efficacy by the patient at the end of treatment (morning of Day 6) is presented. The patient/investigator assessed the overall efficacy of the trial treatment on a 4-point verbal rating scale by answering the question: "How would you rate the overall effect of the trial medication for relieving back or neck pain?" (0 = poor; 1 = fair; 2 = good; 3 = very good).

    Time frame: At the end of treatment (morning of Day 6)

  5. Number of Patients With a Decrease in POMwp of at Least 30% or 50% Between Baseline and Day 2 (Morning, 2 h After Drug Intake)

    Number of patients with a decrease in POMwp of at least 30% or 50% between baseline and Day 2 (morning, 2 h after drug intake.

    Time frame: Baseline and Day 2 (morning, 2 h after drug intake)

  6. Time to First Meaningful POMwp Relief Within 2 h After the First Dose of Trial Medication

    Time to event analysis of patients with first meaningful POMwp relief within 2 h after the first dose of trial medication. The percentage of observed patients with a meaningful POMwp relief within 2 h after the first dose of trial medication was reported. The procedure which resulted in the highest POM at baseline (POMwp) was repeated by the investigator 10, 20, 30, 60 and 120 min after the first dose of trial medication. The POMwp relief score (POMwpRS) was assessed by the patient at each of these time points by using a 5-point verbal rating scale (0 = no POMwp relief; 1 = little or perceptible POMwp relief; 2 = meaningful POMwp relief; 3 = a lot of POMwp relief; 4 = complete POMwp relief). The time to first meaningful POMWP relief was the earliest assessment time point after the first application of the trial medication at which the patient reported a score of ≥2.

    Time frame: Within 2 h after the first dose of trial medication

07

Results

Posted Jun 7, 2019

Participant flow

This was a randomized, placebo and active-controlled, double-blind, 3-arm, parallel trial, comparing the effect of the fixed dose combination of 400 milligram (mg) ibuprofen\&100 mg caffeine versus 400 mg ibuprofen and placebo in patients with acute neck or back pain randomly assigned in 2:2:1 ratio respectively.

Participant flow — Overall Study
MilestonePlaceboIbuprofenIbuprofen and Caffeine
Started126253256
Completed121249251
Not completed545
Withdrew: Adverse event123
Withdrew: Lack of efficacy100
Withdrew: Non-compliant with protocol011
Withdrew: Refused to continue medication200
Withdrew: Other than listed111

Outcome measures

PrimaryChange in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake)

The change in pain on movement (POM) with regard to the worst procedure (WP), i.e. the procedure with the highest pain score at baseline (POMwp), between baseline (morning of Day 1, pre-dosing) and Day 2 (morning, 2 hour (h) after drug intake). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. The procedure resulting in highest POM at baseline (worst procedure, POMWP) was repeated for an individual patient. If 2 or more procedures gave the same highest POM, the patient was asked which of the procedures giving the highest POM scores he/she considered the most unpleasant. Change in POMwp was calculated as baseline POMwp - POMwp at Day 2 - indicating a reduction in POMwp, where the result is positive.

Time frame:
Baseline and Day 2
Reported as:
Least squares mean · Unit on scale
Change in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake)
Unit on scalePlaceboIbuprofenIbuprofen and Caffeine
Change in Pain on Movement (POM) With Regard to the Worst Procedure (WP) Between Baseline and Day 2 (Morning, 2 Hours After Drug Intake)1.712 ± 0.14221.998 ± 0.10421.869 ± 0.1030
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · Mixed effect Model Repeated Measurement · p = 0.3446 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): 0.156 · 95% CI -0.168 to 0.480Adjusted mean change from baseline ibuprofen and caffeine - Adjusted mean change from baseline placebo. A positive result favors the treatment with ibuprofen and caffeine
  • Ibuprofen vs Ibuprofen and Caffeine · Mixed effect Model Repeat Measurement · p = 0.3358 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): -0.129 · 95% CI -0.392 to 0.134Adjusted mean change from baseline ibuprofen and caffeine - Adjusted mean change from baseline ibuprofen. A positive result favors the treatment with ibuprofen and caffeine
SecondaryThe Area Under the Curve (AUC) for Pain on Movement (POM) With Regard to the Worst Procedure (POMwp) Between Baseline and Day 4 (Morning) (POMwpAUC72hour (h))

This is a key secondary endpoint. The area under the curve (AUC) for pain on movement (POM) with regard to the worst procedure (POMwp) between baseline and Day 4 (morning), (POMwpAUC72h ). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp

Time frame:
Baseline, Day 1, Day 2 and Day 4 (morning)
Reported as:
Least squares mean · Unit on scale
The Area Under the Curve (AUC) for Pain on Movement (POM) With Regard to the Worst Procedure (POMwp) Between Baseline and Day 4 (Morning) (POMwpAUC72hour (h))
Unit on scalePlaceboIbuprofenIbuprofen and Caffeine
The Area Under the Curve (AUC) for Pain on Movement (POM) With Regard to the Worst Procedure (POMwp) Between Baseline and Day 4 (Morning) (POMwpAUC72hour (h))4.800 ± 0.12664.461 ± 0.09424.512 ± 0.0931
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · ANCOVA · p = 0.0474 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): -0.288 · 95% CI -0.572 to -0.003Adjusted mean ibuprofen and caffeine - Adjusted mean placebo. A negative result favors ibuprofen and caffeine
  • Ibuprofen vs Ibuprofen and Caffeine · ANCOVA · p = 0.6658 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): 0.051 · 95% CI -0.180 to 0.282Adjusted mean ibuprofen and caffeine - Adjusted mean ibuprofen. A negative result favors ibuprofen and caffeine.
SecondaryThe Area Under the Curve (AUC) for the Procedure With the Highest Pain Score at Baseline (POMWP) Between Baseline and Day 6 (Morning) (POM(WP)AUC(120h))

This is a key secondary endpoint. The area under the curve for pain on movement with regard to the worst procedure between baseline and Day 6 (morning) (POM(WP)AUC(120h). POM was assessed by the patient at the performance of one standardized, muscle group specific movement and was measured by a numerical rating scale ranging from 0 = 'no pain'to 10 = 'worst pain possible for this condition'. A higher AUC value indicates higher POMwp.

Time frame:
Baseline, Day 1, Day 2, Day 4 and Day 6 (morning)
Reported as:
Least squares mean · Unit on scale
The Area Under the Curve (AUC) for the Procedure With the Highest Pain Score at Baseline (POMWP) Between Baseline and Day 6 (Morning) (POM(WP)AUC(120h))
Unit on scalePlaceboIbuprofenIbuprofen and Caffeine
The Area Under the Curve (AUC) for the Procedure With the Highest Pain Score at Baseline (POMWP) Between Baseline and Day 6 (Morning) (POM(WP)AUC(120h))4.175 ± 0.13343.718 ± 0.09923.776 ± 0.0981
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · ANCOVA · p = 0.0091 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): -0.399 · 95% CI -0.698 to -0.100Adjusted mean ibuprofen and caffeine - Adjusted mean placebo. A negative result favors ibuprofen and caffeine
  • Ibuprofen vs Ibuprofen and Caffeine · ANCOVA · p = 0.6387 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): 0.058 · 95% CI -0.185 to 0.302Adjusted mean ibuprofen and caffeine - Adjusted mean ibuprofen. A negative result favors ibuprofen and caffeine
SecondaryChange in Pressure Algometry Between Baseline and Day 2 (Morning, 2 Hour After Drug Intake)

Change in pressure algometry between baseline and Day 2 (morning, 2 h after drug intake). Pressure algometry was determined by the investigator as the pressure value (N/cm2) at a defined trigger point which is located in the area of POMWP. The measurement was performed by using a Somedic Algometer (Somedic AB, Sweden) or an equivalent calibrated and certified device. The pain reaction was determined by placing the algometer on the trigger point, i.e. an area of 1 cm² for which the patient indicated most painful tenderness. The pressure was constantly increased until the patient asked not to increase the pressure anymore. Upon this pain reaction, the corresponding pressure value was documented in the Electronic case report form (eCRF). The trigger point was to be marked with a ball pen to be able to repeat the subsequent assessment at the same position. Change in pressure was calculated as baseline pressure - pressure at Day 2, with a negative result indicating an improvement.

Time frame:
Baseline and Day 2 (morning, 2 h after drug intake)
Reported as:
Least squares mean · newton/centimeter² (N/cm^2)
Change in Pressure Algometry Between Baseline and Day 2 (Morning, 2 Hour After Drug Intake)
newton/centimeter² (N/cm^2)PlaceboIbuprofenIbuprofen and Caffeine
Change in Pressure Algometry Between Baseline and Day 2 (Morning, 2 Hour After Drug Intake)-3.734 ± 0.6107-3.331 ± 0.4396-3.175 ± 0.4366
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · Mixed effect model for repeated measures · p = 0.4398 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): 0.559 · 95% CI -0.861 to 1.979Adjusted mean change ibuprofen and caffeine - Adjusted mean change placebo. A negative result favors ibuprofen and caffeine.
  • Ibuprofen vs Ibuprofen and Caffeine · Mixed effect Model Repeat Measurement · p = 0.7911 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Mean difference (final values): 0.156 · 95% CI -1.002 to 1.314Adjusted mean change ibuprofen and caffeine - Adjusted mean change ibuprofen. A negative result favors ibuprofen and caffeine.
SecondaryGlobal Assessment of Efficacy by the Patient at the End of Treatment (Morning of Day 6)

Global assessment of efficacy by the patient at the end of treatment (morning of Day 6) is presented. The patient/investigator assessed the overall efficacy of the trial treatment on a 4-point verbal rating scale by answering the question: "How would you rate the overall effect of the trial medication for relieving back or neck pain?" (0 = poor; 1 = fair; 2 = good; 3 = very good).

Time frame:
At the end of treatment (morning of Day 6)
Reported as:
Number · Participants
Global Assessment of Efficacy by the Patient at the End of Treatment (Morning of Day 6)
ParticipantsPlaceboIbuprofenIbuprofen and Caffeine
Very good144341
Good46115116
Fair355766
Poor283832
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · Regression, Logistic · p = 0.0045 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 1.777 · 95% CI 1.195 to 2.642An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator
  • Ibuprofen vs Ibuprofen and Caffeine · Regression, Logistic · p = 0.9603 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 1.008 · 95% CI 0.732 to 1.389An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator
SecondaryNumber of Patients With a Decrease in POMwp of at Least 30% or 50% Between Baseline and Day 2 (Morning, 2 h After Drug Intake)

Number of patients with a decrease in POMwp of at least 30% or 50% between baseline and Day 2 (morning, 2 h after drug intake.

Time frame:
Baseline and Day 2 (morning, 2 h after drug intake)
Reported as:
Number · Participants
Number of Patients With a Decrease in POMwp of at Least 30% or 50% Between Baseline and Day 2 (Morning, 2 h After Drug Intake)
ParticipantsPlaceboIbuprofenIbuprofen and Caffeine
Patients with a decrease of ≥30%49111101
Patients with a decrease of ≥50%175944
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · likelihood-ratio test · p = 0.9022 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 1.028 · 95% CI 0.663 to 1.592An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator.
  • Ibuprofen vs Ibuprofen and Caffeine · likelihood-ratio test · p = 0.3129 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 0.834 · 95% CI 0.586 to 1.187An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator.
  • Placebo vs Ibuprofen and Caffeine · likelihood-ratio test · p = 0.3301 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 1.354 · 95% CI 0.736 to 2.494An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator
  • Ibuprofen vs Ibuprofen and Caffeine · likelihood-ratio test · p = 0.0864 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.) · Odds ratio (or): 0.680 · 95% CI 0.437 to 1.057An odds ratio \>1 indicates better efficacy for ibuprofen and caffeine than for the comparator
SecondaryTime to First Meaningful POMwp Relief Within 2 h After the First Dose of Trial Medication

Time to event analysis of patients with first meaningful POMwp relief within 2 h after the first dose of trial medication. The percentage of observed patients with a meaningful POMwp relief within 2 h after the first dose of trial medication was reported. The procedure which resulted in the highest POM at baseline (POMwp) was repeated by the investigator 10, 20, 30, 60 and 120 min after the first dose of trial medication. The POMwp relief score (POMwpRS) was assessed by the patient at each of these time points by using a 5-point verbal rating scale (0 = no POMwp relief; 1 = little or perceptible POMwp relief; 2 = meaningful POMwp relief; 3 = a lot of POMwp relief; 4 = complete POMwp relief). The time to first meaningful POMWP relief was the earliest assessment time point after the first application of the trial medication at which the patient reported a score of ≥2.

Time frame:
Within 2 h after the first dose of trial medication
Reported as:
Number · Percentage of participants
Time to First Meaningful POMwp Relief Within 2 h After the First Dose of Trial Medication
Percentage of participantsPlaceboIbuprofenIbuprofen and Caffeine
0 to ≤10 min1.60.80.8
>10 to ≤20 min1.62.01.2
>20 to ≤30 min1.62.42.0
>30 to ≤60 min5.69.15.5
>60 to <=1208.78.310.2
>120 min000
Statistical analysis
  • Placebo vs Ibuprofen and Caffeine · Log Rank · p = 0.9384 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.)p-value based on a stratified log-rank test
  • Ibuprofen vs Ibuprofen and Caffeine · Log Rank · p = 0.3534 (No adjustment for multiplicity issues was made for this comparison. The level of significance was 0.05.)p-value based on a stratified log-rank test

Adverse events

Collected over From first drug administration until 24 hour after last intake of trial medication, up to 7 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/126 (0%)0/126 (0%)0/126 (0%)
Ibuprofen0/253 (0%)0/253 (0%)0/253 (0%)
Ibuprofen and Caffeine0/256 (0%)0/256 (0%)0/256 (0%)

Baseline characteristics

Treated Set (TS): The TS comprised all randomised patients who took at least 1 dose of trial medication.

Age, Continuous
Age, Continuous(Years)PlaceboIbuprofenIbuprofen and CaffeineTotal
Mean46.3 ± 15.0045.5 ± 16.4044.8 ± 17.0045.4 ± 16.36
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIbuprofenIbuprofen and CaffeineTotal
Female75155143373
Male5198113262
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboIbuprofenIbuprofen and CaffeineTotal
Hispanic or Latino1001
Not Hispanic or Latino125253256634
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIbuprofenIbuprofen and CaffeineTotal
American Indian or Alaska Native1001
Asian0134
Native Hawaiian or Other Pacific Islander0000
Black or African American0325
White125249251625
More than one race0000
Unknown or Not Reported0000
Pain on movement worst procedure score (0-10)
Pain on movement worst procedure score (0-10)(Unit on scale)PlaceboIbuprofenIbuprofen and CaffeineTotal
Mean6.9 ± 1.076.8 ± 1.156.6 ± 1.156.7 ± 1.14
08

Study locations

18 sites
  • Praxis Dr. Steinebach, Essen
    Essen, 45277, Germany
  • Praxis Dr. Schaefer, 45355 Essen
    Essen, 45355, Germany
  • Studienzentrum Bocholderstraße
    Essen, 45355, Germany
  • Unterfrintroper Hausarztzentrum
    Essen, 45359, Germany
  • Praxis Dr. Pabst, Gilching
    Gilching, 82205, Germany
  • Praxis Kai Gastl
    Gilching, 82205, Germany
  • medicoKIT GmbH
    Goch, 47574, Germany
  • Clinical Research Dr. Martz
    Hamburg, 22143, Germany
  • Praxis Dr. Dahmen, 22415 Hamburg
    Hamburg, 22415, Germany
  • Praxis Dr. Chevts, 76199 Karlsruhe
    Karlsruhe, 76199, Germany
  • Dünnwaldpraxis, Köln
    Köln, 51069, Germany
  • Praxis Dr. Klein, Künzing
    Künzing, 94550, Germany
  • Anästhesiologie Rheinbach
    Rheinbach, 53359, Germany
  • Praxis Dr. Sauter
    Wangen, 88239, Germany
  • Neurologie und Psychiatrie / Psychotherapie
    Westerstede, 26655, Germany
  • State Healthcare Institution, City Out-Patient's Clinic #109
    St. Petersburg, 192283, Russian Federation
  • Medical Centre "Reavita Med SPb" LLC
    St. Petersburg, 194325, Russian Federation
  • City Outpatient dep.no.107;clinc.pharmacology,st.petersburg
    St. Petersburg, 195030, Russian Federation
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2016 to primary completion in Sep 2017, 9 months.

Results were first posted in Jun 2019, 1 year 8 months after primary completion.

Of 16 phase 3 interventional studies under Back Pain, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 62. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2016
First posted
Dec 26, 2016
StartActual
Dec 20, 2016
Primary completionActual
Sep 24, 2017
CompletionActual
Sep 28, 2017
Results first posted
Jun 7, 2019
Last update
Jun 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03003000
Responsible party
Sponsor
First posted
Dec 26, 2016
Start date
Dec 20, 2016
Primary completion
Sep 24, 2017
Completion
Sep 28, 2017
Results posted
Jun 7, 2019
Last update
Jun 7, 2019

Study contacts

Boehringer Ingelheim
study chair · Boehringer Ingelheim
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Caffeine

Start the discussion